Reata Pharmaceuticals Q1 EPS $(1.16) Beats $(2.10) Estimate
Reata Pharmaceuticals (NASDAQ:RETA) reported quarterly losses of $(1.16) per share which beat the analyst consensus estimate of $(2.10) by 44.76 percent. This is a 21.09 percent increase over losses of $(1.47) per share